Tumor Biology

, Volume 36, Issue 2, pp 515–520 | Cite as

High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis

  • HeLi Gao
  • Mei Guan
  • Zhao Sun
  • ChunMei Bai


Recent studies have shown that c-Met is an important signal in the development of colorectal cancer, but the prognostic value of c-Met remains unclear. We aimed to analyze the prognostic effect of c-Met in colorectal cancer through a systematic review and meta-analysis. Through database searches, we identified six articles describing how c-Met status affects colorectal cancer prognosis. A meta-analysis was performed to investigate the relationship between the hazard ratio and survival. The available outcome data from six articles were examined. A meta-analysis of the HR and the 95 % confidence interval (CI) indicated a significantly poor overall survival and disease-free survival in patients with high expression levels of c-Met. The subgroup analysis showed that the prognostic effect of the c-Met level was similar in different methods and was not associated with disease stages. High c-Met expression levels could predict a poor prognosis in colorectal cancer patients. The c-Met status could be used to evaluate the prognosis in clinical patients.


c-Met Colorectal cancer Prognosis Meta-analysis 


Conflicts of interest


Author contributions

GHL and GM contributed to the literature searching and writing of the manuscript. SZ performed the statistical analysis. BCM participated in study design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.


  1. 1.
    Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277–300.CrossRefPubMedGoogle Scholar
  3. 3.
    Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One. 2009;4:e7287.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis—correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met. Tumour Biol. 2013;34(4):2109–17.CrossRefPubMedGoogle Scholar
  5. 5.
    Gherardi E, Birchmeier W, Birchmeier C, Vande WG. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89–103.CrossRefPubMedGoogle Scholar
  6. 6.
    Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Color Dis. 2013;28(1):9–18.CrossRefGoogle Scholar
  7. 7.
    Liu Y, Li Q, Zhu L. Expression of the hepatocyte growth factor and c-Met in colon cancer: correlation with clinicopathological features and overall survival. Tumori. 2012;98(1):105–12.PubMedGoogle Scholar
  8. 8.
    Qian LY, Li P, Li XR, Chen DJ, Zhu SH. Multivariate analysis of molecular indicators for postoperative liver metastasis in colorectal cancer cases. Asian Pac J Cancer Prev. 2012;13(8):3967–71.CrossRefPubMedGoogle Scholar
  9. 9.
    GA Wells, B Shea and D O’Connell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available:
  10. 10.
    Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Umeki K, Shiota G, Kawasaki H. Clinical significance of c-met oncogene alterations in human colorectal cancer. Oncology. 1999;56(4):314–21.CrossRefPubMedGoogle Scholar
  12. 12.
    De Oliveira AT, Matos D, Logullo AF, DA Silva SR, Neto RA, Filho AL, et al. MET is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res. 2009;29(11):4807–11.PubMedGoogle Scholar
  13. 13.
    Lee CT, Chow NH, Su PF, Lin SC, Lin PC, Lee JC. The prognostic significance of RON and MET receptor co-expression in patients with colorectal cancer. Dis Colon Rectum. 2008;51(8):1268–74.CrossRefPubMedGoogle Scholar
  14. 14.
    Uddin S, Hussain AR, Ahmed M, Al-Sanea N, Abduljabbar A, Ashari LH, et al. Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma. Am J Pathol. 2011;179(6):3032–44.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 2007;248(2):219–28.CrossRefPubMedGoogle Scholar
  16. 16.
    Osada S, Matsui S, Komori S, Yamada J, Sanada Y, Ihawa A, et al. Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer. Hepatogastroenterology. 2010;57(97):76–80.PubMedGoogle Scholar
  17. 17.
    Abou-Bakr AA, Elbasmi A. c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma. Gulf J Oncol. 2013;1(14):28–34.Google Scholar
  18. 18.
    Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, et al. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer. 2011;10(4):325–32.CrossRefPubMedGoogle Scholar
  19. 19.
    Ginty F, Adak S, Can A, Gerdes M, Larsen M, Cline H, et al. The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer. Clin Cancer Res. 2008;14:3814–22.CrossRefPubMedGoogle Scholar
  20. 20.
    Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res. 2004;10:3069–75.CrossRefPubMedGoogle Scholar
  21. 21.
    Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 2008;265:258–69.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M, et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res. 2003;9:1480–8.PubMedGoogle Scholar
  23. 23.
    Otte JM, Schmitz F, Kiehne K, Stechele HU, Banasiewicz T, Krokowicz P, et al. Functional expression of HGF and its receptor in human colorectal cancer. Digestion. 2001;61:237–46.CrossRefGoogle Scholar
  24. 24.
    Samadi AK, Cohen SM, Mukerji R, Chaguturu V, Zhang X, Timmermann BN, et al. Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation. Tumour Biol. 2012;33(4):1179–89.CrossRefPubMedGoogle Scholar
  25. 25.
    Yu S, Yu Y, Zhao N, Cui J, Li W, Liu T. c-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. Plos One. 2013;8(11):e79137.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Trusolino L, Comoglio PM. Scatter-factor and semaphoring receptors: cell signaling for invasive growth. Nat Rev Cancer. 2002;2:289–300.CrossRefPubMedGoogle Scholar
  27. 27.
    Matsui S, Osada S, Tomita H, Komori S, Mori R, Sanada Y, et al. Clinical significance of aggressive hepatectomy for colorectal liver metastasis, evaluated from the HGF/c-Met pathway. Int J Oncol. 2010;37:289–97.PubMedGoogle Scholar
  28. 28.
    Coskun U, Bukan N, Sancak B, Gunel N, Ozenirler S, Unal A, et al. Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions. Neoplasma. 2004;51:209–13.PubMedGoogle Scholar
  29. 29.
    Migliore C, Giordano S. Molecular cancer therapy: can our expectation be MET? Eur J Cancer. 2008;44:641–51.CrossRefPubMedGoogle Scholar
  30. 30.
    Toschi L, Janne P. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin Cancer Res. 2008;14:5941–6.CrossRefPubMedGoogle Scholar
  31. 31.
    D’Arcangelo M, Cappuzzo F. Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer. Biogeosciences. 2013;7:61–8.Google Scholar
  32. 32.
    Tan E, Park K, Lim WT, Ahn M, Ng QS, Ahn JS, et al. Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor monoclonal antibody in combination with gefitinib in Asian patients with NSCLC. J Clin Oncol. 2011;29:7571.CrossRefGoogle Scholar
  33. 33.
    Chen HJ, Mok TS, Chen ZH, Guo AL, Zhang XC, Su J, et al. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res. 2009;15:651–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17:77–88.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Oncology, Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations